Skip to main content

Advertisement

Springer Nature Link
Log in

Mechanism of tumor remission by cytomegalovirus in a murine lymphoma model: evidence for involvement of virally induced cellular interleukin-15

  • Original Investigation
  • Published:
Medical Microbiology and Immunology Aims and scope Submit manuscript

Abstract

A murine model of B and T cell lymphomas in recipients after hematoablative conditioning for hematopoietic cell transplantation (HCT) has previously revealed a tumor-repressive, metastasis-inhibiting function of murine cytomegalovirus (mCMV). More recently, this prediction from the experimental model was put on trial in several clinical studies that indeed gave evidence for a lower incidence of tumor relapse associated with early reactivation of latent human cytomegalovirus (hCMV) after allogeneic HCT in patients treated against different types of hematopoietic malignancies, including lymphoma and acute as well as chronic leukemias. Due to the limitations inherent to clinical studies, the tumor-repressive role of hCMV remained observational with no approach to clarify mechanisms. Although the tumor-repressive mechanisms of mCMV and hCMV may differ and depend on the type of tumor, experimental approaches in the murine model might give valuable hints for concepts to follow in clinical research. We have previously shown for the liver-adapted A20-derived B cell lymphoma E12E that mCMV does not infect the lymphoma cells for causing cell death by viral cytopathogenicity but triggers tumor-selective apoptosis at a tissue site of tumor metastasis distant from a local site of infection. This finding suggested involvement of a cytokine that triggers apoptosis, directly or indirectly. Here we used a series of differential high-density microarray analyses to identify cellular genes whose expression is specifically upregulated at the site of virus entry only by viruses capable of triggering lymphoma cell apoptosis. This strategy identified interleukin-15 (IL-15) as most promising candidate, eventually confirmed by lymphoma repression with recombinant IL-15.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411:385–389

    Article  CAS  PubMed  Google Scholar 

  2. Appelbaum FR (2003) The current status of hematopoietic cell transplantation. Annu Rev Med 54:491–512

    Article  CAS  PubMed  Google Scholar 

  3. Hebart H, Einsele H (2004) Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 65:432–436

    Article  CAS  PubMed  Google Scholar 

  4. Seo S, Boeckh M (2013) Clinical cytomegalovirus research: hematopoietic cell transplantation. In: Reddehase MJ (ed) Cytomegaloviruses: from molecular pathogenesis to intervention, vol II, Chap 16. Caister Academic Press, Norfolk, pp 337–353

    Google Scholar 

  5. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103:767–776

    Article  CAS  PubMed  Google Scholar 

  6. Reusser P, Riddell SR, Meyers JD, Greenberg PD (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380

    CAS  PubMed  Google Scholar 

  7. Loren AW, Porter DL (2008) Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transpl 41:483–493

    Article  CAS  Google Scholar 

  8. Roddie C, Peggs KS (2011) Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 11:473–487

    Article  PubMed  Google Scholar 

  9. Moss P, Rickinson A (2005) Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol 5:9–20

    Article  CAS  PubMed  Google Scholar 

  10. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044

    Article  CAS  PubMed  Google Scholar 

  11. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, Mackinnon S (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362:1375–1377

    Article  PubMed  Google Scholar 

  12. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss PA (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202:379–386

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, Mohty M, Or R, Maschan M, Schumm M, Hamprecht K, Handgretinger R, Lang P, Einsele H (2010) Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116:4360–4367

    Article  CAS  PubMed  Google Scholar 

  14. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, Germeroth L, Ringhoffer M, Ringhoffer S, Wiesneth M, Greiner J, Michel D, Mertens T, Rojewski M, Marx M, von Harsdorf S, Döhner H, Seifried E, Bunjes D, Schmitt M (2011) Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 51:591–599

    Article  CAS  PubMed  Google Scholar 

  15. Fujiwara H, Matsumoto T, Eizuru Y, Matsushita K, Ohtsubo H, Kukita T, Imaizumi R, Matsumoto M, Hidaka S, Arima N, Tei C (2000) Cytomegalovirus infection is not necessarily a poor prognostic factor in adult T-cell leukemia/lymphoma. J Med Virol 62:140–143

    Article  CAS  PubMed  Google Scholar 

  16. Fujiwara H, Eizuru Y, Matsumoto T, Kukita T, Imaizumi R, Kawada H, Ohtsubo H, Matsushita K, Arima N, Tei C (2001) The significance of cytomegalovirus infection over the clinical course of adult T-cell leukemia/lymphoma. Microbiol Immunol 45:97–100

    Article  CAS  PubMed  Google Scholar 

  17. Erlach KC, Podlech J, Rojan A, Reddehase MJ (2002) Tumor control in a model of bone marrow transplantation and acute liver-infiltrating B-cell lymphoma: an unpredicted novel function of cytomegalovirus. J Virol 76:2857–2870

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Erlach KC, Böhm V, Seckert CK, Reddehase MJ, Podlech J (2006) Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection. J Virol 80:4801–4819

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Erlach KC, Böhm V, Knabe M, Deegen P, Reddehase MJ, Podlech J (2008) Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection. Med Microbiol Immunol 197:167–178

    Article  CAS  PubMed  Google Scholar 

  20. Podlech J, Holtappels R, Wirtz N, Steffens HP, Reddehase MJ (1998) Reconstitution of CD8 T-cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J Gen Virol 79:2099–2104

    CAS  PubMed  Google Scholar 

  21. Sacher T, Podlech J, Mohr CA, Jordan S, Ruzsics Z, Reddehase MJ, Koszinowski UH (2008) The major virus-producing cell type during murine cytomegalovirus infection, the hepatocyte, is not the source of virus dissemination in the host. Cell Host Microbe 3:263–272

    Article  CAS  PubMed  Google Scholar 

  22. Lemmermann NA, Krmpotic A, Podlech J, Brizic I, Prager A, Adler H, Karbach A, Wu Y, Jonjic S, Reddehase MJ, Adler B (2015) Non-redundant and redundant roles of cytomegalovirus gH/gL complexes in host organ entry and intra-tissue spread. PLoS Pathog 11:e1004640

    Article  PubMed  Google Scholar 

  23. Bradbury J (2001) Oncolytic viral anti-cancer therapy: a magic bullet? Lancet 357:614

    Article  CAS  PubMed  Google Scholar 

  24. Cicin-Sain L, Podlech J, Messerle M, Reddehase MJ, Koszinowski UH (2005) Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host. J Virol 79:9492–9502

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, Christoph S, Gromke T, Kordelas L, Ottinger HD, Ross RS, Horn PA, Schnittger S, Beelen DW (2011) Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118:1402–1412

    Article  CAS  PubMed  Google Scholar 

  26. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, Riddell SR, Boeckh M (2013) CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122:1316–1324

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R (2014) Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transpl 20:46–52

    Article  CAS  Google Scholar 

  28. Ito S, Pophali P, Co W, Koklanaris EK, Superata J, Fahle GA, Childs R, Battiwalla M, Barrett AJ (2013) CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transpl 48:1313–1316

    Article  CAS  Google Scholar 

  29. Barrett AJ (2011) CMV: when bad viruses turn good. Blood 118:1193–1194

    Article  CAS  PubMed  Google Scholar 

  30. Thomson KJ, Mackinnon S, Peggs KS (2012) CMV-specific cellular therapy for acute myeloid leukemia? Blood 119:1088–1090

    Article  CAS  PubMed  Google Scholar 

  31. Ljungman P (2013) CMV: a warrior against leukemia? Blood 122:1101–1102

    Article  CAS  PubMed  Google Scholar 

  32. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D, Anderson D (1994) Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13:2822–2830

    PubMed Central  CAS  PubMed  Google Scholar 

  33. Anderson DM, Kumaki S, Ahdieh M, Bertles J, Tometsko M, Loomis A, Giri J, Copeland NG, Gilbert DJ, Jenkins NA, Valentine V, Shapiro DN, Morris SW, Park LS, Cosman D (1995) Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2 RA genes. J Biol Chem 270:29862–29869

    Article  CAS  PubMed  Google Scholar 

  34. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR, Pande VS, Li P, Moraga I, Spolski R, Ozkan E, Leonard WJ, Garcia KC (2012) Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 13:1187–1195

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM, Alt FW (1992) RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855–867

    Article  CAS  PubMed  Google Scholar 

  36. Jacobs H, Krimpenfort P, Haks M, Allen J, Blom B, Demolliere C, Kruisbeek A, Spits H, Berns A (1999) PIM1 reconstitutes thymus cellularity in interleukin 7- and common gamma chain-mutant mice and permits thymocyte maturation in Rag- but not CD3 gamma-deficient mice. J Exp Med 190:1059–1068

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Shenk T (2006) Human cytomegalovirus genomics. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology, Chap 3. Caister Academic Press, Norfolk, pp 49–61

    Google Scholar 

  38. Marcinowski L, Lidschreiber M, Windhager L, Rieder M, Bosse JB, Rädle B, Bonfert T, Györy I, de Graaf M, Prazeres da Costa O, Rosenstiel P, Friedel CC, Zimmer R, Ruzsics Z, Dölken L (2012) Real-time transcriptional profiling of cellular and viral gene expression during lytic cytomegalovirus infection. PLoS Pathog 8:e1002908

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Juranic Lisnic V, Babic Cac M, Lisnic B, Trsan T, Mefferd A, Das Mukhopadhyay C, Cook CH, Jonjic S, Trgovcich J (2013) Dual analysis of the murine cytomegalovirus and host cell transcriptomes reveal new aspects of the virus-host cell interface. PLoS Pathog 9:e1003611

    Article  PubMed Central  PubMed  Google Scholar 

  40. Ghazal P, Visser AE, Gustems M, Garcia R, Borst EM, Sullivan K, Messerle M, Angulo A (2005) Elimination of ie1 significantly attenuates murine cytomegalovirus virulence but does not alter replicative capacity in cell culture. J Virol 79:7182–7194

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Rodriguez-Martin S, Kropp KA, Wilhelmi V, Lisnic VJ, Hsieh WY, Blanc M, Livingston A, Busche A, Tekotte H, Messerle M, Auer M, Fraser I, Jonjic S, Angulo A, Reddehase MJ, Ghazal P (2012) Ablation of the regulatory IE1 protein of murine cytomegalovirus alters in vivo pro-inflammatory TNF-alpha production during acute infection. PLoS Pathog 8:e1002901

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Gribaudo G, Riera L, Lembo D, De Andrea M, Gariglio M, Rudge TL, Johnson LF, Landolfo S (2000) Murine cytomegalovirus stimulates cellular thymidylate synthase gene expression in quiescent cells and requires the enzyme for replication. J Virol 74:4979–4987

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Lembo D, Gribaudo G, Hofer A, Riera L, Cornaglia M, Mondo A, Angeretti A, Gariglio M, Thelander L, Landolfo S (2000) Expression of an altered ribonucleotide reductase activity associated with the replication of murine cytomegalovirus in quiescent fibroblasts. J Virol 74:11557–11565

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Wilhelmi V, Simon CO, Podlech J, Böhm V, Däubner T, Emde S, Strand D, Renzaho A, Lemmermann NAW, Seckert CK, Reddehase MJ, Grzimek NK (2008) Transactivation of cellular genes involved in nucleotide metabolism by the regulatory IE1 protein of murine Cytomegalovirus is not critical for viral replicative fitness in quiescent cells and host tissues. J Virol 82:9900–9916

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, Caligiuri MA, Durbin JE, Biron CA (2002) Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169:4279–4287

    Article  CAS  PubMed  Google Scholar 

  46. Dalod M, Biron CA (2013) Immunoregulatory cytokine networks discovered and characterized during murine cytomegalovirus infections. In: Reddehase MJ (ed) Cytomegaloviruses: from molecular pathogenesis to intervention, vol II, Chap 11. Caister Academic Press, Norfolk, pp 232–258

    Google Scholar 

  47. Epardaud M, Elpek KG, Rubinstein MP, Yonekura A-R, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ (2008) Interleukin-15/Interleukin-15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 68:2972–2983

    Article  CAS  PubMed  Google Scholar 

  48. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H (1984) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312:548–551

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Deutsche Forschungsgemeinschaft, collaborative research grant SFB432, individual project A10 ‘Influence of cytomegalovirus infection on the risk of leukemia relapse after HCT’, and the Clinical Research Group KFO183. The authors thank the team of the High Density Microarray (HDMA) Core Facility of the SFB432, central project Z6 (Özlem Türeci and Ulrich Luxemburger) for having expertly performed the HDMA analyses with all quality controls, and for advice in data interpretation.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

All procedures performed in studies involving animals were approved by the ethics committee of the Landesuntersuchungsamt Rheinland-Pfalz, permission no. 1.5 177-07-04/051-56 in accordance with German Federal Law §8 Abs. 1 TierSchG (animal protection law). BALB/c mice and H-2d;BALB-RAG2γc mice were bred and housed under specified pathogen-free conditions at the Central Laboratory Animal Facility (CLAF) at the University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

Author information

Author notes

  1. Katja C. Erlach

    Present address: Roche Diagnostics Deutschland GmbH, Sandhofer Strasse 116, 68305, Mannheim, Germany

Authors and Affiliations

  1. Institute for Virology, University Medical Center of the Johannes Gutenberg-University Mainz and Research Center for Immunotherapy (FZI), Obere Zahlbacher Strasse 67, Hochhaus am Augustusplatz, 55131, Mainz, Germany

    Katja C. Erlach, Matthias J. Reddehase & Jürgen Podlech

Authors
  1. Katja C. Erlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias J. Reddehase
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Podlech
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Podlech.

Additional information

This article is part of the Special Issue on Cytomegalovirus.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erlach, K.C., Reddehase, M.J. & Podlech, J. Mechanism of tumor remission by cytomegalovirus in a murine lymphoma model: evidence for involvement of virally induced cellular interleukin-15. Med Microbiol Immunol 204, 355–366 (2015). https://doi.org/10.1007/s00430-015-0408-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00430-015-0408-z

Keywords

Search

Navigation